Upson drops IPO price by 56%

Upson International [UPSON 2.40 pre-IPO] [link] has priced its IPO at P2.40/share, a 56% drop from the maximum price of P5.50/share that UPSON used in its preliminary prospectus. The owners also drastically cut the number of shares that will be up for sale, from a total of 986 million shares down to just 687.5 million.
The primary/secondary split of the deal was also changed; the over-allotment option is still made of secondary shares, but the secondary portion of the main offer has been removed. This raises the proportion of primary shares in the deal to 90%, up from 80%. Together, the changes in price and shares offered will reduce the overall value of the IPO from P5.4 billion to P1.6 billion.
MB BOTTOM-LINE
That’s a massive 70% drop in the deal’s overall value, but this is not unprecedented. Figaro [FCG 0.90 10.9%] reduced its deal size by 56% through a similar combination of price cut and offer size reduction, and I referred to that as a “staggering” change. When FCG did it, I said that FCG had stripped the offering down to its “bare essentials”, to make sure that the sale would be ”optimally advantageous” to the interests of its owner, Jerry Liu.
But I made that call based on my experience with Jerry Liu as a savvy public markets operator. I don’t have the same experience with UPSON’s owner, Lawrence O. Lee. The underwriter teams are different between the two deals as well, so it makes it very hard to draw any conclusions from just the fact that the deal size was so aggressively chopped down.
Is UPSON desperate to get to the market under any conditions, or was the initial prospectus just a bit of fun wishful thinking that was never going to represent the real deal to any of the parties involved? The preliminary prospectus had said that UPSON would use P3.5 billion of the IPO for store network expansion of 50 stores in 2023 and 250 stores over the next three years, and P0.6 billion for general corporate purposes. I’m very curious to see how this will be updated in the final prospectus.
--
Merkado Barkada's opinions are provided for informational purposes only, and should not be considered a recommendation to buy or sell any particular stock. These daily articles are not updated with new information, so each investor must do his or her own due diligence before trading, as the facts and figures in each particular article may have changed.
- Latest














